- 現金殖利率: 2.14%、總殖利率: 2.14%、5年平均現金配發率: 85.09%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 2.18 | 0.93 | 1.50 | -25.0 | 0.00 | 0 | 68.81 | -25.69 | 0.00 | 0 | 68.81 | -25.69 |
| 2022 (9) | 2.16 | 32.52 | 2.00 | 37.93 | 0.00 | 0 | 92.59 | 4.09 | 0.00 | 0 | 92.59 | 4.09 |
| 2021 (8) | 1.63 | -22.75 | 1.45 | -24.48 | 0.00 | 0 | 88.96 | -2.24 | 0.00 | 0 | 88.96 | -2.24 |
| 2020 (7) | 2.11 | -1.4 | 1.92 | 6.67 | 0.00 | 0 | 91.00 | 8.18 | 0.00 | 0 | 91.00 | 8.18 |
| 2019 (6) | 2.14 | 12.63 | 1.80 | 9.09 | 0.00 | 0 | 84.11 | -3.14 | 0.00 | 0 | 84.11 | -3.14 |
| 2018 (5) | 1.90 | -4.52 | 1.65 | -8.33 | 0.00 | 0 | 86.84 | -3.99 | 0.00 | 0 | 86.84 | -3.99 |
| 2017 (4) | 1.99 | -5.69 | 1.80 | -5.26 | 0.00 | 0 | 90.45 | 0.45 | 0.00 | 0 | 90.45 | 0.45 |
| 2016 (3) | 2.11 | 0.48 | 1.90 | 8.57 | 0.00 | 0 | 90.05 | 8.06 | 0.00 | 0 | 90.05 | 8.06 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 0.47 | -6.0 | 4.44 | 0.42 | -4.55 | 0.0 | 1.43 | 48.96 | -24.74 |
| 24Q2 (19) | 0.50 | 11.11 | -33.33 | 0.44 | 4.76 | -10.2 | 0.96 | 113.33 | -36.0 |
| 24Q1 (18) | 0.45 | -8.16 | -40.0 | 0.42 | 27.27 | -14.29 | 0.45 | -79.91 | -40.0 |
| 23Q4 (17) | 0.49 | 8.89 | -20.97 | 0.33 | -21.43 | -21.43 | 2.24 | 17.89 | 3.7 |
| 23Q3 (16) | 0.45 | -40.0 | -29.69 | 0.42 | -14.29 | 0.0 | 1.90 | 26.67 | 23.38 |
| 23Q2 (15) | 0.75 | 0.0 | 56.25 | 0.49 | 0.0 | 58.06 | 1.50 | 100.0 | 66.67 |
| 23Q1 (14) | 0.75 | 20.97 | 78.57 | 0.49 | 16.67 | 68.97 | 0.75 | -65.28 | 78.57 |
| 22Q4 (13) | 0.62 | -3.13 | 47.62 | 0.42 | 0.0 | 44.83 | 2.16 | 40.26 | 31.71 |
| 22Q3 (12) | 0.64 | 33.33 | 45.45 | 0.42 | 35.48 | 44.83 | 1.54 | 71.11 | 26.23 |
| 22Q2 (11) | 0.48 | 14.29 | 11.63 | 0.31 | 6.9 | 6.9 | 0.90 | 114.29 | 15.38 |
| 22Q1 (10) | 0.42 | 0.0 | 20.0 | 0.29 | 0.0 | 31.82 | 0.42 | -74.39 | 20.0 |
| 21Q4 (9) | 0.42 | -4.55 | -4.55 | 0.29 | 0.0 | 0.0 | 1.64 | 34.43 | -22.64 |
| 21Q3 (8) | 0.44 | 2.33 | -6.38 | 0.29 | 0.0 | -6.45 | 1.22 | 56.41 | -26.95 |
| 21Q2 (7) | 0.43 | 22.86 | -27.12 | 0.29 | 31.82 | -27.5 | 0.78 | 122.86 | -35.0 |
| 21Q1 (6) | 0.35 | -20.45 | -42.62 | 0.22 | -24.14 | -45.0 | 0.35 | -83.49 | -42.62 |
| 20Q4 (5) | 0.44 | -6.38 | -38.89 | 0.29 | -6.45 | -38.3 | 2.12 | 26.95 | -1.4 |
| 20Q3 (4) | 0.47 | -20.34 | 0.0 | 0.31 | -22.5 | 0.0 | 1.67 | 39.17 | 0.0 |
| 20Q2 (3) | 0.59 | -3.28 | 0.0 | 0.40 | 0.0 | 0.0 | 1.20 | 96.72 | 0.0 |
| 20Q1 (2) | 0.61 | -15.28 | 0.0 | 0.40 | -14.89 | 0.0 | 0.61 | -71.63 | 0.0 |
| 19Q4 (1) | 0.72 | 0.0 | 0.0 | 0.47 | 0.0 | 0.0 | 2.15 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 0.5 | 9.34 | -2.49 | 5.13 | 2.05 | 1.54 | N/A | - | ||
| 2024/9 | 0.46 | -22.6 | -6.48 | 4.64 | 2.57 | 1.5 | 0.93 | - | ||
| 2024/8 | 0.59 | 29.7 | 11.67 | 4.18 | 3.66 | 1.57 | 0.88 | - | ||
| 2024/7 | 0.45 | -13.97 | -2.17 | 3.59 | 2.46 | 1.48 | 0.94 | - | ||
| 2024/6 | 0.53 | 6.52 | -17.04 | 3.14 | 3.16 | 1.5 | 0.88 | - | ||
| 2024/5 | 0.5 | 3.32 | -0.74 | 2.61 | 8.52 | 1.49 | 0.89 | - | ||
| 2024/4 | 0.48 | -6.57 | 15.46 | 2.11 | 10.96 | 1.39 | 0.95 | - | ||
| 2024/3 | 0.51 | 28.38 | -16.3 | 1.63 | 9.7 | 1.63 | 0.75 | - | ||
| 2024/2 | 0.4 | -44.25 | 5.26 | 1.12 | 27.97 | 1.62 | 0.76 | - | ||
| 2024/1 | 0.72 | 42.12 | 45.47 | 0.72 | 45.47 | 1.75 | 0.7 | - | ||
| 2023/12 | 0.51 | -4.81 | -3.82 | 6.07 | 22.64 | 1.55 | 0.9 | - | ||
| 2023/11 | 0.53 | 3.73 | 20.19 | 5.56 | 25.79 | 1.53 | 0.91 | - | ||
| 2023/10 | 0.51 | 4.86 | 15.05 | 5.03 | 26.41 | 1.53 | 0.91 | - | ||
| 2023/9 | 0.49 | -7.57 | 13.26 | 4.52 | 27.84 | 1.48 | 0.9 | - | ||
| 2023/8 | 0.53 | 13.61 | 33.06 | 4.03 | 29.86 | 1.63 | 0.82 | - | ||
| 2023/7 | 0.46 | -27.04 | 5.96 | 3.5 | 29.39 | 1.6 | 0.83 | - | ||
| 2023/6 | 0.64 | 27.45 | 51.8 | 3.04 | 33.92 | 1.55 | 0.82 | 因受到流感、腸病毒及新冠疫情影響，相關藥品出貨量增加，及反映原物料上漲調整藥品售價，使得6月單月營收較去年同期大幅成長。 | ||
| 2023/5 | 0.5 | 20.19 | 32.2 | 2.4 | 29.87 | 1.53 | 0.83 | - | ||
| 2023/4 | 0.42 | -32.28 | 12.89 | 1.9 | 29.27 | 1.41 | 0.9 | - | ||
| 2023/3 | 0.61 | 61.47 | 69.9 | 1.49 | 34.73 | 1.49 | 0.77 | 112年3月單月合併營收較去年同期成長69.90%，係因自112年3月起部分產品調整售價及市場需求量增加，以致營收成長。 | ||
| 2023/2 | 0.38 | -22.97 | 9.97 | 0.87 | 17.62 | 1.4 | 0.81 | - | ||
| 2023/1 | 0.49 | -6.04 | 24.28 | 0.49 | 24.28 | 1.46 | 0.78 | - | ||
| 2022/12 | 0.53 | 18.96 | 41.52 | 4.95 | 20.21 | 1.41 | 0.9 | - | ||
| 2022/11 | 0.44 | -0.7 | 26.49 | 4.42 | 18.1 | 1.32 | 0.96 | - | ||
| 2022/10 | 0.44 | 3.23 | 28.93 | 3.98 | 17.23 | 1.27 | 1.0 | - | ||
| 2022/9 | 0.43 | 8.58 | 22.43 | 3.54 | 15.91 | 1.27 | 1.07 | - | ||
| 2022/8 | 0.4 | -9.52 | 20.14 | 3.1 | 15.06 | 1.25 | 1.08 | - | ||
| 2022/7 | 0.44 | 4.51 | 36.32 | 2.71 | 14.35 | 1.24 | 1.1 | - | ||
| 2022/6 | 0.42 | 10.99 | 31.33 | 2.27 | 10.9 | 1.17 | 1.16 | - | ||
| 2022/5 | 0.38 | 2.63 | 9.15 | 1.85 | 7.12 | 1.11 | 1.22 | - | ||
| 2022/4 | 0.37 | 1.9 | 14.0 | 1.47 | 6.62 | 1.08 | 1.26 | - | ||
| 2022/3 | 0.36 | 4.51 | 6.87 | 1.1 | 4.36 | 1.1 | 1.21 | - | ||
| 2022/2 | 0.35 | -12.94 | 8.09 | 0.74 | 3.18 | 1.11 | 1.2 | - | ||
| 2022/1 | 0.4 | 6.98 | -0.73 | 0.4 | -0.73 | 1.12 | 1.2 | - | ||
| 2021/12 | 0.37 | 6.33 | -4.46 | 4.11 | -2.95 | 1.06 | 1.37 | - | ||
| 2021/11 | 0.35 | 1.2 | 12.0 | 3.74 | -2.8 | 1.05 | 1.4 | - | ||
| 2021/10 | 0.34 | -1.96 | 3.18 | 3.39 | -4.1 | 1.03 | 1.42 | - | ||
| 2021/9 | 0.35 | 6.54 | 10.87 | 3.05 | -4.86 | 1.0 | 1.52 | - | ||
| 2021/8 | 0.33 | 2.66 | 0.88 | 2.7 | -6.59 | 0.97 | 1.58 | - | ||
| 2021/7 | 0.32 | 0.68 | -21.35 | 2.37 | -7.54 | 0.99 | 1.55 | - | ||
| 2021/6 | 0.32 | -7.74 | 1.74 | 2.05 | -4.92 | 0.99 | 1.46 | - | ||
| 2021/5 | 0.35 | 7.19 | 21.75 | 1.73 | -6.06 | 1.01 | 1.43 | - | ||
| 2021/4 | 0.32 | -4.46 | -14.18 | 1.38 | -11.15 | 0.98 | 1.47 | - | ||
| 2021/3 | 0.34 | 5.71 | -22.4 | 1.06 | -10.18 | 1.06 | 1.46 | - | ||
| 2021/2 | 0.32 | -20.05 | -18.11 | 0.72 | -3.01 | 1.11 | 1.39 | - | ||
| 2021/1 | 0.4 | 2.97 | 13.74 | 0.4 | 13.74 | 1.1 | 1.4 | - | ||
| 2020/12 | 0.39 | 24.65 | -18.48 | 4.24 | -0.31 | 1.03 | 1.53 | - | ||
| 2020/11 | 0.31 | -6.75 | -13.42 | 3.85 | 1.98 | 0.96 | 1.64 | - | ||
| 2020/10 | 0.33 | 5.33 | -17.57 | 3.54 | 3.6 | 0.98 | 1.61 | - | ||
| 2020/9 | 0.32 | -3.05 | 4.06 | 3.21 | 6.45 | 1.05 | 1.34 | - | ||
| 2020/8 | 0.33 | -19.96 | -4.12 | 2.89 | 6.72 | 1.05 | 1.34 | - | ||
| 2020/7 | 0.41 | 30.25 | 21.04 | 2.56 | 8.29 | 1.01 | 1.4 | - | ||
| 2020/6 | 0.31 | 10.4 | -1.31 | 2.15 | 6.16 | 0.97 | 1.45 | - | ||
| 2020/5 | 0.28 | -24.44 | -18.34 | 1.84 | 7.56 | 1.1 | 1.29 | - | ||
| 2020/4 | 0.38 | -13.62 | 8.72 | 1.55 | 14.18 | 1.2 | 1.17 | - | ||
| 2020/3 | 0.44 | 11.56 | 30.73 | 1.18 | 16.05 | 1.18 | 0.97 | - | ||
| 2020/2 | 0.39 | 11.03 | 76.98 | 0.74 | 8.87 | 1.22 | 0.94 | 109年2月單月合併營收較去年同期成長76.99%，係因108年2月適逢年節假期，營收較低所致 | ||
| 2020/1 | 0.35 | -26.19 | -23.72 | 0.35 | -23.72 | 1.19 | 0.96 | - | ||
| 2019/12 | 0.48 | 32.38 | 48.81 | 4.25 | 3.25 | 0.0 | N/A | - | ||
| 2019/11 | 0.36 | -11.22 | 7.92 | 3.78 | -0.58 | 0.0 | N/A | - |
